Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late
JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)...
Source: globenewswire.com
Facilitates Chimerism News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Facilitates Chimerism. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.